1
|
Tonna JE, Boonstra PS, MacLaren G, Paden M, Brodie D, Anders M, Hoskote A, Ramanathan K, Hyslop R, Fanning JJ, Rycus P, Stead C, Barrett NA, Mueller T, Gómez RD, Kapoor PM, Fraser JF, Bartlett RH, Alexander PM, Barbaro RP. Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors. ASAIO J 2024; 70:131-143. [PMID: 38181413 PMCID: PMC10962646 DOI: 10.1097/mat.0000000000002128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2024] Open
Abstract
The Extracorporeal Life Support Organization (ELSO) maintains the world's largest extracorporeal membrane oxygenation (ECMO) registry by volume, center participation, and international scope. This 2022 ELSO Registry Report describes the program characteristics of ECMO centers, processes of ECMO care, and reported outcomes. Neonates (0-28 days), children (29 days-17 years), and adults (≥18 years) supported with ECMO from 2009 through 2022 and reported to the ELSO Registry were included. This report describes adjunctive therapies, support modes, treatments, complications, and survival outcomes. Data are presented descriptively as counts and percent or median and interquartile range (IQR) by year, group, or level. Missing values were excluded before calculating descriptive statistics. Complications are reported per 1,000 ECMO hours. From 2009 to 2022, 154,568 ECMO runs were entered into the ELSO Registry. Seven hundred and eighty centers submitted data during this time (557 in 2022). Since 2009, the median annual number of adult ECMO runs per center per year increased from 4 to 15, whereas for pediatric and neonatal runs, the rate decreased from 12 to 7. Over 50% of patients were transferred to the reporting ECMO center; 20% of these patients were transported with ECMO. The use of prone positioning before respiratory ECMO increased from 15% (2019) to 44% (2021) for adults during the coronavirus disease-2019 (COVID-19) pandemic. Survival to hospital discharge was greatest at 68.5% for neonatal respiratory support and lowest at 29.5% for ECPR delivered to adults. By 2022, the Registry had enrolled its 200,000th ECMO patient and 100,000th patient discharged alive. Since its inception, the ELSO Registry has helped centers measure and compare outcomes across its member centers and strategies of care. Continued growth and development of the Registry will aim to bolster its utility to patients and centers.
Collapse
Affiliation(s)
- Joseph E. Tonna
- Division of Cardiothoracic Surgery, Department of Surgery, University of Utah Health, Salt Lake City, Utah
- Department of Emergency Medicine, University of Utah Health, Salt Lake City, Utah
| | - Philip S. Boonstra
- Department of Biostatistics, University of Michigan, Ann Arbor, Michigan
| | - Graeme MacLaren
- Cardiothoracic Intensive Care Unit, National University Hospital, Singapore, Singapore
| | - Matthew Paden
- Department of Surgery, Division of Pediatric Critical Care Medicine, Emory University School of Medicine, Atlanta, Georgia
| | - Daniel Brodie
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Marc Anders
- Department of Surgery, Division of Critical Care, Texas Children’s Hospital, Baylor College of Medicine, Houston, Texas
| | - Aparna Hoskote
- Department of Surgery, Heart and Lung Directorate, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
- Department of Surgery, Institute of Cardiovascular Science, University College London, Zayed Centre for Research into Rare Diseases in Children, London, UK
| | - Kollengode Ramanathan
- Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- Department of Surgery, Cardiothoracic Intensive Care Unit, National University Heart Centre, National University Hospital, Singapore, Singapore
| | - Rob Hyslop
- Department of Surgery, Heart Institute, Children’s Hospital Colorado, Aurora, Colorado
| | - Jeffrey J. Fanning
- Department of Pediatrics, Extracorporeal Life Support Program, Medical City Children’s Hospital, Dallas, Texas
| | - Peter Rycus
- Department of Surgery, Extracorporeal Life Support Organization (ELSO), Ann Arbor, Michigan
| | - Christine Stead
- Department of Surgery, Extracorporeal Life Support Organization (ELSO), University of Michigan, Ann Arbor, Michigan
| | - Nicholas A. Barrett
- Department of Critical Care, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
- Department of Surgery, Centre for Human & Applied Physiological Sciences, King’s College London, London, UK
| | - Thomas Mueller
- Intensive Care Medicine, Department of Internal Medicine II, University Hospital Regensburg, Germany
| | - Rene D. Gómez
- Department of Surgery, Terapias Avanzadas de Soporte Cardiopulmonar, Hospitales Tec Salud, Escuela de Medicina ITESM, Monterrey, Mexico
| | - Poonam Malhotra Kapoor
- Department of Cardiac Anaesthesiology and Critical Care, Cardio Thoracic Centre, All India Institute of Medical Sciences (AIIMS), New Delhi, India
| | - John F. Fraser
- Department of Surgery, University of Queensland, The Prince Charles Hospital, Brisbane, Australia
| | | | - Peta M.A. Alexander
- Department of Cardiology, Boston Children’s Hospital, Boston, Massachusetts
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts
| | - Ryan P. Barbaro
- Division of Critical Care Medicine, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan
- Department of Surgery, Susan B. Meister Child Health Evaluation and Research Center, University of Michigan, Ann Arbor, Michigan
| |
Collapse
|
2
|
Griffee MJ, Bozza PT, Reyes LF, Eddington DP, Rosenberger D, Merson L, Citarella BW, Fanning JP, Alexander PM, Fraser J, Dalton H, Cho SM. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry. Res Pract Thromb Haemost 2023; 7:102142. [PMID: 37601011 PMCID: PMC10439444 DOI: 10.1016/j.rpth.2023.102142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Revised: 05/29/2023] [Accepted: 06/08/2023] [Indexed: 08/22/2023] Open
Abstract
Background COVID-19 has been associated with a broad range of thromboembolic, ischemic, and hemorrhagic complications (coagulopathy complications). Most studies have focused on patients with severe disease from high-income countries (HICs). Objectives The main aims were to compare the frequency of coagulopathy complications in developing countries (low- and middle-income countries [LMICs]) with those in HICs, delineate the frequency across a range of treatment levels, and determine associations with in-hospital mortality. Methods Adult patients enrolled in an observational, multinational registry, the International Severe Acute Respiratory and Emerging Infections COVID-19 study, between January 1, 2020, and September 15, 2021, met inclusion criteria, including admission to a hospital for laboratory-confirmed, acute COVID-19 and data on complications and survival. The advanced-treatment cohort received care, such as admission to the intensive care unit, mechanical ventilation, or inotropes or vasopressors; the basic-treatment cohort did not receive any of these interventions. Results The study population included 495,682 patients from 52 countries, with 63% from LMICs and 85% in the basic treatment cohort. The frequency of coagulopathy complications was higher in HICs (0.76%-3.4%) than in LMICs (0.09%-1.22%). Complications were more frequent in the advanced-treatment cohort than in the basic-treatment cohort. Coagulopathy complications were associated with increased in-hospital mortality (odds ratio, 1.58; 95% CI, 1.52-1.64). The increased mortality associated with these complications was higher in LMICs (58.5%) than in HICs (35.4%). After controlling for coagulopathy complications, treatment intensity, and multiple other factors, the mortality was higher among patients in LMICs than among patients in HICs (odds ratio, 1.45; 95% CI, 1.39-1.51). Conclusion In a large, international registry of patients hospitalized for COVID-19, coagulopathy complications were more frequent in HICs than in LMICs (developing countries). Increased mortality associated with coagulopathy complications was of a greater magnitude among patients in LMICs. Additional research is needed regarding timely diagnosis of and intervention for coagulation derangements associated with COVID-19, particularly for limited-resource settings.
Collapse
Affiliation(s)
- Matthew J. Griffee
- Department of Anesthesiology, University of Utah, Salt Lake City, Utah, USA
- ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom
| | - Patricia T. Bozza
- Laboratory of Immunopharmacology, Institutio Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Luis Felipe Reyes
- Unisabana Center for Translational Science, School of Medicine, Universidad de La Sabana, Chia, Colombia
| | - Devin P. Eddington
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA
| | | | - Laura Merson
- ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, United Kingdom
| | | | | | - Peta M.A. Alexander
- Department of Cardiology, Boston Children’s Hospital, Boston, Massachusetts, USA
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA
| | - John Fraser
- Critical Care Research Group, The Prince Charles Hospital, University of Queensland, Brisbane, Australia
| | - Heidi Dalton
- Pediatric Critical Care Medicine, Heart and Vascular Institute, Inova Fairfax Hospital, Annandale, Virginia, USA
| | - Sung-Min Cho
- Divisions of Neuroscience Critical Care and Cardiac Surgery, Departments of Neurology, Surgery, Anesthesia and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| |
Collapse
|
6
|
Alexander PM, Daubeney PE, Nugent AW, Lee KJ, Turner C, Colan SD, Robertson T, Davis AM, Ramsay J, Justo R, Sholler GF, King I, Weintraub RG. Long-Term Outcomes of Dilated Cardiomyopathy Diagnosed During Childhood. Circulation 2013; 128:2039-46. [DOI: 10.1161/circulationaha.113.002767] [Citation(s) in RCA: 107] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Existing studies of childhood dilated cardiomyopathy deal mainly with early survival. This population-based study examines long-term outcomes for children with dilated cardiomyopathy.
Methods and Results—
The diagnosis of dilated cardiomyopathy was based on clinical, echocardiographic, and pathological findings. The primary study end point included time to the combined outcome of death or cardiac transplantation. There were 175 patients 0 to <10 years of age at the time of diagnosis. Survival free from death or transplantation was 74% (95% confidence interval, 67–80) 1 year after diagnosis, 62% (95% confidence interval, 55–69) at 10 years, and 56% (95% confidence interval, 46–65) at 20 years. In multivariable analysis, age at diagnosis <4 weeks or >5 years, familial cardiomyopathy, and lower baseline left ventricular fractional shortening
Z
score were associated with increased risk of death or transplantation, as was lower left ventricular fractional shortening
Z
score during follow-up. At 15 years after diagnosis, echocardiographic normalization had occurred in 69% of surviving study subjects. Normalization was related to higher baseline left ventricular fractional shortening
Z
score, higher left ventricular fractional shortening
Z
score during follow-up, and greater improvement in left ventricular fractional shortening
Z
score. Children with lymphocytic myocarditis had better survival and a higher rate of echocardiographic normalization. At the latest follow-up, 100 of 104 of survivors (96%) were free of cardiac symptoms, and 83 (80%) were no longer receiving pharmacotherapy.
Conclusions—
Death or transplantation occurred in 26% of patients with childhood dilated cardiomyopathy within 1 year of diagnosis and ~1% per year thereafter. Risk factors for death or transplantation include age at diagnosis, familial cardiomyopathy, and severity of left ventricular dysfunction. The majority of surviving subjects are well and free of cardiac medication.
Collapse
Affiliation(s)
- Peta M.A. Alexander
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Piers E.F. Daubeney
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Alan W. Nugent
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Katherine J. Lee
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Christian Turner
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Steven D. Colan
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Terry Robertson
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Andrew M. Davis
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - James Ramsay
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Robert Justo
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Gary F. Sholler
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Ingrid King
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| | - Robert G. Weintraub
- From The Royal Children’s Hospital, Melbourne, Victoria, Australia (P.M.A.A., A.M.D., R.G.W.); Murdoch Children’s Research Institute, Melbourne, Victoria, Australia (P.M.A.A., K.J.L., A.M.D., I.K., R.G.W.); Royal Brompton Hospital and the National Heart and Lung Institute, Imperial College, London, UK (P.E.F.D.); University of Texas Southwestern Medical Center, Dallas (A.W.N.); University of Melbourne, Melbourne, Victoria, Australia (K.J.L.); Children’s Hospital at Westmead, Sydney, New South Wales,
| |
Collapse
|